Short Interest in Henry Schein, Inc. (NASDAQ:HSIC) Decreases By 6.8%

Henry Schein, Inc. (NASDAQ:HSIC) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 5,500,000 shares, a drop of 6.8% from the March 15th total of 5,900,000 shares. Based on an average daily trading volume, of 1,140,000 shares, the short-interest ratio is currently 4.8 days. Currently, 4.3% of the shares of the stock are sold short.

Henry Schein Price Performance

Henry Schein stock opened at $70.20 on Thursday. The company has a current ratio of 1.67, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $9.02 billion, a P/E ratio of 22.29, a PEG ratio of 1.75 and a beta of 0.87. The business has a 50-day moving average of $74.53 and a 200-day moving average of $72.50. Henry Schein has a 1 year low of $60.01 and a 1 year high of $85.39.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.04). The firm had revenue of $3.02 billion during the quarter, compared to the consensus estimate of $3 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The firm’s revenue for the quarter was down 10.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.21 EPS. On average, equities analysts anticipate that Henry Schein will post 5.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on HSIC shares. Leerink Partnrs restated a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. Jefferies Financial Group upped their price target on Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a research note on Wednesday, March 6th. SVB Leerink started coverage on Henry Schein in a report on Monday, February 26th. They issued a “market perform” rating and a $78.00 price target on the stock. TheStreet raised Henry Schein from a “c+” rating to a “b-” rating in a report on Monday, February 26th. Finally, Evercore ISI raised their target price on shares of Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $81.09.

Insider Transactions at Henry Schein

In other news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares in the company, valued at approximately $15,585,125.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Institutional Trading of Henry Schein

Several hedge funds have recently added to or reduced their stakes in the business. McGlone Suttner Wealth Management Inc. bought a new stake in shares of Henry Schein in the fourth quarter worth about $39,000. Baystate Wealth Management LLC increased its stake in Henry Schein by 2,500.0% during the 3rd quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Henry Schein during the 3rd quarter worth approximately $46,000. Covestor Ltd lifted its stake in Henry Schein by 88.4% in the first quarter. Covestor Ltd now owns 861 shares of the company’s stock valued at $75,000 after buying an additional 404 shares in the last quarter. Finally, Harbour Investments Inc. boosted its holdings in shares of Henry Schein by 27,725.0% in the fourth quarter. Harbour Investments Inc. now owns 1,113 shares of the company’s stock valued at $84,000 after buying an additional 1,109 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.